WHY DO WE COMBINE LB WITH AMOXYCLAV 625

WHY DO WE COMBINE LB WITH AMOXYCLAV 625

Today lets discuss on the crucial role Lactobacillus plays when administered as an adjuvant with Amoxicillin-Clavulanic acid (AmoxyClav-625).

Amoxicillin-Clavulanic acid is a broad-spectrum antibiotic widely used to treat bacterial infections. However, like other antibiotics, it can disturb the natural gut flora, leading to adverse effects such as diarrhea , bloating, or secondary infections like Clostridioides difficile-associated diarrhea. This is where Lactobacillus, a probiotic, becomes essential.

Role of Lactobacillus as an Adjuvant:

Restoration of Gut Microbiota: Lactobacillus, being a beneficial bacterium, helps in recolonizing the gut with healthy microbiota after the disruption caused by antibiotics. This minimises gastrointestinal side effects, including antibiotic-associated diarrhea (AAD), which is a common concern during prolonged antibiotic therapy.

Immuno-modulatory Effects: Studies have shown that Lactobacillus strains can modulate the immune system by enhancing mucosal immunity. This can help reduce the risk of superinfections or secondary infections while the primary infection is being treated by Amoxiclav.

Improved Patient Compliance: By reducing gastrointestinal side effects, Lactobacillus ensures better patient compliance, which is vital in antibiotic treatments. Patients are less likely to discontinue or skip doses due to discomfort, leading to better outcomes and fewer instances of antibiotic resistance development.

Preventing Overgrowth of Pathogens: Probiotic strains like Lactobacillus help in maintaining a balanced microbial environment, preventing the overgrowth of harmful bacteria and fungi, which can occur when antibiotics disrupt the normal flora. This is especially beneficial in preventing conditions like candidiasis or other opportunistic infections during antibiotic therapy.

A growing body of research supports the efficacy of combining Lactobacillus with broad-spectrum antibiotics like Amoxiclav. For instance, clinical studies demonstrate a significant reduction in antibiotic-associated diarrhea when Lactobacillus is co-administered, with improved gut health outcomes in patients undergoing long-term antibiotic treatment.

The use of Lactobacillus as an adjuvant therapy with AmoxyClav 625, hence, is a well-rounded approach to mitigating the adverse gastrointestinal effects commonly associated with antibiotic use. By safeguarding the gut microbiome, enhancing immune function, and preventing opportunistic infections, Lactobacillus ensures that patients not only recover from their bacterial infections but also maintain overall gastrointestinal health.

This combination is a win-win for clinicians aiming to enhance therapeutic efficacy while minimizing complications associated with antibiotic therapy.

Regards,

Amit Katoch,

JAKSTAR PHARMA

Sandeep Bhattacharya

Managing Director at AUREAX Healthcare Consulting Pvt Ltd

1 个月

The only problem is that the Lactobacillus spores get killed in the stomach and hence provide no protection. The real problem of Co-Amoxiclav is that most brands, other than Augnentin, have very low bioavailability, hence they remain in the gut & destroy flora causing diarrhea by 3rd or 4th day. Good bioavailability would allow two weeks of therapy without affecting the flora.

Atul Phatak

Experienced business development professional clinical research Phase I to Phase IV.

1 个月

Thanks for this very informative and useful post Sir

要查看或添加评论,请登录

AMIT KATOCH的更多文章

社区洞察

其他会员也浏览了